Jilin YATAI Group Pharmaceutical Investment Co., Ltd. (Yatai Pharme) is a joint-stock modern hi-tech pharmaceutical enterprise, established in September 1999 co-invested by Jilin YATAI (Group) Co., Ltd. and Tianfu Science & Technology Co., Ltd located in Dalian Economic-Technological Development Zone. Yatai Pharme locates at No.109, Changtong Road,Nanshan Street, Jiutai, Jilin, with a plant area of 41,846 sq.m., and engages in the production of tablet, capsules and granules. The registered capital of Yatai Pharme is RMB 83.15 million. As of 31 December 2014, the total assets of Yatai Pharme was RMB 306 million, with an annual sales of RMB 250 million, an annual profit of RMB 49.3 million and the paid taxes and dues of all kinds of RMB 47 million.
    Yatai Pharme now has 281 employees respectively from the Quality Management Department, Production Management Department,Comprehensive Management Department, Human Resource Management, Financial Department and Sales Department. The modern management team of Yatai Pharme consisting of young, talented, high-quality and competitive members not only improves the operation efficiency of the enterprise but also guarantees the human resource required for the sustainable development of the enterprise.  
     Yatai Pharme mainly engages in the production and sales of ginsenoside Rg3 (a Class I new anticancer drug of monomer of Chinese traditional herb subject to independent property rights) and its preparations “Shenyi Capsule”, which have a good effect on inhibiting the tumor and metastasis as a tumor angiogenesis inhibitor independently developed by Yatai.The major functions of “Shenyi Capsule” aim at relieving to an extent the symptoms of lung cancer, liver cancer,stomach cancer, breast cancer, esophagus cancer, leukemia and other malignant tumors, which are effective in treatment. 
    In 2000, Yatai Pharme officially acquired the certificate of national Class I new traditional Chinese medicine and the documents approving the trial production of such medicines. In February 2010, Yatai Pharme obtained the quality standard documents approving the official production and sales of the aforesaid drugs as issued by the State Food and Drug Administration (SFDA). On 6 September 2013, the SFDA issued the certificate certifying that “Shenyi Capsule” is a“National Class II Traditional Chinese Medicine Under Protection”. Since 2006, “Shenyi Capsule” had been listed in the NCCN Clinical Practice Guidelines in Oncology (Chinese Version) as one of the first-line drugs for successive 6 years.
    In 2012, “Shenyi Capsule” was accepted by the Guidelines on the TCM Treatment of Tumor as a standard medicine for thyroid, lung cancer and breast cancer, etc. At present, Yatai Pharme have built a marketing network covering the whole nation, in which case,“Shenyi Capsule” has played its role in more than 500 middle-large size hospitals widely spreading in 28 provinces, autonomous regions and municipalities directly under the central government, with a stable and good development orientation.  
    Upon the marketing of “Shenyi Capsule”, it has won the support by more than 10 national major scientific projects.In June 2000, “Shenyi Capsule” was awarded as the National Key New Product by the Ministry of Science and Technology. In October 2000,“Shenyi Capsule” was awarded by the People’s Government of Jilin Province as the Excellent New Product of Jilin Province. In May 2001, “Shenyi Capsule” was awarded by the State Economic and Trade Commission as the 2001 National Key New Product. 2002-2015, “Shenyi Capsule” has been listed by the Ministry of Science and Technology for 3 times as the topic drugs for scientific problem tackling plans of national “10th five-year plan”,“11th five-year plan” and “12th five-year plan”. In August 2003 and August 2008, Yatai Pharme have passed the national GMP certification for 2 times. In March 2000, August 2003, July 2012 and August 2015, Yatai Pharme has been honored as the hi-tech enterprise of Jilin Province by the S&T Office of Jilin Province for 4 times. Yatai Pharme has won the title of “Small and Medium Business Innovation Fund Project” awarded by the Ministry of Science and Technology respectively in 2004 and 2010. On 10 January 2014, by virtue of the creation and application of key technologies regarding "Shenyi Capsule", a Class I New drug of monomer of Chinese traditional herb subject to independent intelligent property rights, Yatai Pharme won the second award of 2013 National S&T Invention Prize.On 12 October 2014, the “National Class I TCM Shenyi Capsule Crude Drug” has successfully passed the acceptance by the Innovation Fund Management Center of the Ministry of Science and Technology. In August 2015, the“Industrialization of National Class I Monomer of Chinese Traditional Herb - Shenyi Capsule” was listed in the national “Double 10th Engineering” as a significant transformation of scientific achievements. 
    Based on the 16-year development of Yatai Pharme, it stick to the principles of people oriented, innovation and
factualism. Under the proper leadership of Yatai Group, Yatai Pharme's leaders and whole employees are strict,
careful, practical and positive with the work, aiming at making great breakthroughs.
    For the future development, Yatai Pharme keeps the “promotion of human health and creation of life source” as own duty, aims at “providing all patients with high-quality products and service”, in order to make new progress,achieve new development and lead the Chinese modern pharmaceutical enterprises.
    Yatai Pharme intends to initiate a new era by innovation, profit generation and investment, for the purpose of making more contribution to China and society.